Gene · 2230
Papers1,417
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,417
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| OTUB1/CDYL axis-mediated epigenetic repression of SOX18 facilitates lung cancer progression by inhibiting FDX1-dependent cuproptosis. | Oncogene | 2026 | 41912773 | PubTator, text mining | PubMed |
| Programmed cell death: a promising management for Alzheimer's disease. | Apoptosis | 2026 | 41904723 | PubTator, text mining | PubMed |
| Ferroptosis and Cuproptosis in Cancer and Neurodegeneration: A Comprehensive Review of Modulation by Iron and Copper Chelators and Related Agents. | Biomolecules | 2026 | 41897286 | PubTator, text mining | PubMed |
| Dermal Exposure to Heavy Metals in Urban Green Space Soils: A Review of Bioavailability, Toxic Mechanisms, and Precision Risk Assessment. | Toxics | 2026 | 41893504 | PubTator, text mining | PubMed |
| Multifaceted Role of Copper Homeostasis in Gut Health: From Molecular Mechanisms to Therapeutic Interventions. | Cells | 2026 | 41892335 | PubTator, text mining | PubMed |
| Tobacco Rattle Virus Coat Protein Targets Ferredoxin 1 for Degradation. | Mol Plant Pathol | 2026 | 41889145 | PubTator, text mining | PubMed |
| Cuproptosis in spinal cord injury: emerging mechanisms and immunological relevance. | Ann Med | 2026 | 41883033 | PubTator, text mining | PubMed |
| Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications. | Signal Transduct Target Ther | 2026 | 41881983 | PubTator, text mining | PubMed |
| SNHG7 interacts with PCBP2 to promote CDKN2A expression and modulate cuproptosis in colorectal cancer. | Transl Oncol | 2026 | 41875809 | PubTator, text mining | PubMed |
| Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity. | Infect Dis Rep | 2026 | 41874145 | PubTator, text mining | PubMed |
| Nuclear translocation of mitochondrial ferredoxin reductase is regulated by AKT-mediated phosphorylation. | Biochem J | 2026 | 41860465 | PubTator, text mining | PubMed |
| Role of Ferredoxin 1 (FDX1) in cancer and its therapeutic potential. | Cancer Pathog Ther | 2026 | 41853121 | PubTator, text mining | PubMed |
| The role of copper and cuproptosis in digestive system cancers: novel therapeutic strategies and mechanistic insights. | Cancer Biol Ther | 2026 | 41837409 | PubTator, text mining | PubMed |
Comprehensive analyses of biological function and tumor microenvironment with cuproptosis regulators and construction of a cuproptosis-related scoring system in thyroid cancer based on bioinformatics and experimental validation. | Front Genet | 2026 | 41836061 | PubTator, text mining | PubMed |
| Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer. | Clin Immunol | 2026 | 41831585 | PubTator, text mining | PubMed |
| Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut. | Sci Adv | 2026 | 41824583 | PubTator, text mining | PubMed |
| The EZH2-NEAT1 epigenetic axis promotes cuproptosis sensitivity and modulates cancer cell migration in colorectal cancer. | J Gastrointest Oncol | 2026 | 41816582 | PubTator, text mining | PubMed |
| Paeoniflorin-Copper-Coordinated Nanoparticles Targeting Dual Organelles Induce Lung Cancer Apoptosis. | Mol Pharm | 2026 | 41810719 | PubTator, text mining | PubMed |
| XN@CuO/HA nanobipyramids trigger FOXO1-GADD45G-mediated cuproptosis and synergy with anti-PD-1 for lung cancer therapy. | Mater Today Bio | 2026 | 41809377 | PubTator, text mining | PubMed |
| Therapeutic horizons of cuproptosis: bibliometric mapping of copper-dependent cell death research and its pharmacological implications. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 41806032 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2230/papers?page=5